Telles-Silva Kayque Alves, Pacheco Lara, Komatsu Sabrina, Chianca Fernanda, Caires-Júnior Luiz Carlos, Araujo Bruno Henrique Silva, Goulart Ernesto, Zatz Mayana
Human Genome and Stem-Cell Research Center (HUG-CEL), Institute of Biosciences, University of Sao Paulo (USP), Sao Paulo, Brazil.
Lieber Institute for Brain Development, School of Medicine, Johns Hopkins University, Baltimore, MD, United States.
Front Bioeng Biotechnol. 2022 Feb 14;10:845360. doi: 10.3389/fbioe.2022.845360. eCollection 2022.
The liver is the most important metabolic hub of endo and xenobiotic compounds. Pre-clinical studies using rodents to evaluate the toxicity of new drugs and cosmetics may produce inconclusive results for predicting clinical outcomes in humans, moreover being banned in the European Union. Human liver modeling using primary hepatocytes presents low reproducibility due to batch-to-batch variability, while iPSC-derived hepatocytes in monolayer cultures (2D) show reduced cellular functionality. Here we review the current status of the two most robust approaches in improving hepatocyte phenotype and metabolism while mimicking the hepatic physiological microenvironment: organoids and liver-on-chip. Both technologies are reviewed in design and manufacturing techniques, following cellular composition and functionality. Furthermore, drug screening and liver diseases modeling efficiencies are summarized. Finally, organoid and liver-on-chip technologies are compared regarding advantages and limitations, aiming to guide the selection of appropriate models for translational research and the development of such technologies.
肝脏是内源性和外源性化合物最重要的代谢枢纽。使用啮齿动物评估新药和化妆品毒性的临床前研究,在预测人类临床结果时可能产生不确定的结果,此外在欧盟已被禁止。使用原代肝细胞进行的人类肝脏建模由于批次间的变异性而呈现出低重现性,而二维单层培养中诱导多能干细胞衍生的肝细胞则显示出细胞功能降低。在此,我们综述了在模拟肝脏生理微环境的同时改善肝细胞表型和代谢的两种最可靠方法的现状:类器官和芯片肝脏。这两种技术将在设计和制造技术、细胞组成和功能方面进行综述。此外,还总结了药物筛选和肝脏疾病建模的效率。最后,对类器官和芯片肝脏技术的优缺点进行了比较,旨在指导为转化研究选择合适的模型以及此类技术的开发。